Drug Profile
Fasaret - Apoplogic Pharmaceuticals
Alternative Names: AP-300Latest Information Update: 19 Sep 2023
Price :
$50
*
At a glance
- Originator ApopLogic Pharmaceuticals
- Class Antineoplastics; Gene therapies; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Solid tumours (Adjuvant therapy) in USA (unspecified route) (Apoplogic Pharmaceuticals pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours(Adjuvant therapy) in USA
- 25 Aug 2016 Fasaret is available for licensing as of 25 Aug 2016. http://www.apoplogic.com/